File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1200/JCO.23.00152
- Scopus: eid_2-s2.0-85170110290
- PMID: 37384848
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Title | Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions |
---|---|
Authors | |
Issue Date | 10-Sep-2023 |
Publisher | American Society of Clinical Oncology |
Citation | Journal of Clinical Oncology, 2023, v. 41, n. 26, p. 4218-4225 How to Cite? |
Abstract | PURPOSEAlthough several agents targeting epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition of wild-type (WT) EGFR are common with these agents and affect overall tolerability. Zipalertinib (CLN-081, TAS6417) is an oral EGFR tyrosine kinase inhibitor (TKI) with a novel pyrrolopyrimidine scaffold leading to enhanced selectivity for EGFR ex20ins-mutant versus WT EGFR with potent inhibition of cell growth in EGFR ex20ins-positive cell lines.METHODSThis phase 1/2a study of zipalertinib enrolled patients with recurrent or metastatic EGFR ex20ins-mutant non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.RESULTSSeventy-three patients were treated with zipalertinib at dose levels including 30, 45, 65, 100, and 150 mg orally twice a day. Patients were predominantly female (56%), had a median age of 64 years, and were heavily pretreated (median previous systemic therapies 2, range 1-9). Thirty six percent of patients had received previous non-ex20ins EGFR TKIs and 3/73 (4.1%) patients received previous EGFR ex20ins TKIs. The most frequently reported treatment-related adverse events of any grade included rash (80%), paronychia (32%), diarrhea (30%), and fatigue (21%). No cases of grade 3 or higher drug-related rash or diarrhea were observed at 100 mg twice a day or below. Objective responses occurred across all zipalertinib dose levels tested, with confirmed partial response (PR) observed in 28/73 (38.4%) response-evaluable patients. Confirmed PRs were seen in 16/39 (41%) response-evaluable patients at the dose of 100 mg twice a day.CONCLUSIONZipalertinib has encouraging preliminary antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile, including low frequency of high-grade diarrhea and rash. |
Persistent Identifier | http://hdl.handle.net/10722/346149 |
ISSN | 2023 Impact Factor: 42.1 2023 SCImago Journal Rankings: 10.639 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Piotrowska, Zofia | - |
dc.contributor.author | Tan, Daniel Shao Weng | - |
dc.contributor.author | Smit, Egbert F. | - |
dc.contributor.author | Spira, Alexander I. | - |
dc.contributor.author | Soo, Ross A. | - |
dc.contributor.author | Nguyen, Danny | - |
dc.contributor.author | Lee, Victor Ho Fun | - |
dc.contributor.author | Yang, James Chih Hsin | - |
dc.contributor.author | Velcheti, Vamsidhar | - |
dc.contributor.author | Wrangle, John M. | - |
dc.contributor.author | Socinski, Mark A. | - |
dc.contributor.author | Koczywas, Marianna | - |
dc.contributor.author | Janik, John E. | - |
dc.contributor.author | Jones, Jeffrey | - |
dc.contributor.author | Yu, Helena Alexandra | - |
dc.date.accessioned | 2024-09-12T00:30:30Z | - |
dc.date.available | 2024-09-12T00:30:30Z | - |
dc.date.issued | 2023-09-10 | - |
dc.identifier.citation | Journal of Clinical Oncology, 2023, v. 41, n. 26, p. 4218-4225 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | http://hdl.handle.net/10722/346149 | - |
dc.description.abstract | PURPOSEAlthough several agents targeting epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition of wild-type (WT) EGFR are common with these agents and affect overall tolerability. Zipalertinib (CLN-081, TAS6417) is an oral EGFR tyrosine kinase inhibitor (TKI) with a novel pyrrolopyrimidine scaffold leading to enhanced selectivity for EGFR ex20ins-mutant versus WT EGFR with potent inhibition of cell growth in EGFR ex20ins-positive cell lines.METHODSThis phase 1/2a study of zipalertinib enrolled patients with recurrent or metastatic EGFR ex20ins-mutant non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.RESULTSSeventy-three patients were treated with zipalertinib at dose levels including 30, 45, 65, 100, and 150 mg orally twice a day. Patients were predominantly female (56%), had a median age of 64 years, and were heavily pretreated (median previous systemic therapies 2, range 1-9). Thirty six percent of patients had received previous non-ex20ins EGFR TKIs and 3/73 (4.1%) patients received previous EGFR ex20ins TKIs. The most frequently reported treatment-related adverse events of any grade included rash (80%), paronychia (32%), diarrhea (30%), and fatigue (21%). No cases of grade 3 or higher drug-related rash or diarrhea were observed at 100 mg twice a day or below. Objective responses occurred across all zipalertinib dose levels tested, with confirmed partial response (PR) observed in 28/73 (38.4%) response-evaluable patients. Confirmed PRs were seen in 16/39 (41%) response-evaluable patients at the dose of 100 mg twice a day.CONCLUSIONZipalertinib has encouraging preliminary antitumor activity in heavily pretreated patients with EGFR ex20ins-mutant NSCLC, with an acceptable safety profile, including low frequency of high-grade diarrhea and rash. | - |
dc.language | eng | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.ispartof | Journal of Clinical Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions | - |
dc.type | Article | - |
dc.identifier.doi | 10.1200/JCO.23.00152 | - |
dc.identifier.pmid | 37384848 | - |
dc.identifier.scopus | eid_2-s2.0-85170110290 | - |
dc.identifier.volume | 41 | - |
dc.identifier.issue | 26 | - |
dc.identifier.spage | 4218 | - |
dc.identifier.epage | 4225 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.issnl | 0732-183X | - |